Dr. Myron S. Czuczman joined the staff of Roswell Park Cancer Institute in 1992, as attending physician, Department of Medicine, and was appointed Head of the Lymphoma/Myeloma Service in 1998 and became a member of the Tumor Immunology Program in 2002 where he heads a Lymphoma Translational Research Laboratory in the Department of Immunology funded by NIH, State, and philanthropic grants. He is also a Professor of Oncology at Roswell Park Cancer Institute and a Professor of Medicine at the University at Buffalo (UB) School of Medicine and Biomedical Sciences.
Dr. Czuczman earned his medical degree from Pennsylvania State University College of Medicine in 1985. He completed internship and residency training at Cornell’s North Shore University Hospital/Memorial Sloan-Kettering Cancer Program (1985-1988). Between 1988 and 1992, Dr. Czuczman completed a fellowship in Medical Oncology/Hematology and a senior research fellowship in Hematopoietic Cancer Immunochemistry at Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Czuczman is licensed by New York State, certified by the American Board of Medical Oncology and is a Diplomate in Internal Medicine.
Lymphoma research interests focus on monoclonal antibodies either alone or in combination with other agents in the treatment of lymphoma, evaluating novel target-specific molecules active against lymphoma in the clinic and laboratory, and studying the mechanisms-of-action and resistance pathways involving monoclonal antibodies and other novel agents currently used in the treatment of lymphoid neoplasms. His clinical research has contributed to approval by the U.S. Food and Drug Administration of the first monoclonal therapy - rituximab - for non-Hodgkin’s lymphoma in 1997. He was the first investigator to publish on the ability to successfully combine rituximab with standard chemotherapy in 1999 which was the “springboard” for additional research which changed the standard treatment approach of mature B-cell neoplasms from chemotherapy-based to immunochemotherapy-based world-wide.
Dr. Czuczman’s Lymphoma Translational Research Laboratory was the first to develop and extensively characterize “rituximab-resistant” cell lines by which the “acquirement” of resistance was associated with a significant decrease in expression of “target” protein (i.e. CD20), as well as an unexpected changes in the balance of apoptotic proteins which made the cells resistant to anti-lymphoma chemotherapy drugs. His lab is actively evaluating 2nd-generation anti-CD20 antibodies (e.g. veltuzumab, ofatumumab, etc.), and several novel agents in development for the treatment of lymphoma. In addition, his laboratory is also involved in evaluating the importance of proteasome inhibition with respect to its impact on lymphoma resistance as part of a NIH-funded R01 grant. He also is interested in the study of tumor microenvironment and its potential as a target for lymphoma therapy. Lenalidomide (aka Revlimid) and pomalidomide are being studied in his laboratory and he is the PI of a global Phase II/III randomized (FDA registrational) trial of lenalidomide salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Dr. Czuczman is a member of the American Association of Cancer Research, the American Society of Hematology and the American Society of Clinical Oncology. He also serves on the National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines Panel, the NCCN non-Hodgkin’s Lymphoma Outcomes Database Panel and is a cadre member of the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB) national cooperative group.
Dr. Czuczman has authored or co-authored more than 380 journal publications, book chapters and abstracts. He is a journal reviewer for the Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Blood, Cancer Investigation, Annals of Hematology, Cancer Research, American Journal of Hematology, American Journal of Oncology Review, Oncology, Clinical Lymphoma, and British Journal of Haematology. He is also on the Editorial Board of The American Journal of Oncology Review, NHL Updates (Darwin Medical Communications), Targeted Therapies, Current Hematologic Malignancy Reports, Clinical Lymphoma and Myeloma, Therapeutic Advances in Hematology, and Expert Opinion on Biological Therapy.
Dr. Czuczman is recognized as a leader in the field of novel targeted therapies for NHL and related neoplasms and has lectured both nationally and internationally on this topic.